Large-cap health care company Bristol-Myers Squibb Company has moved -0.7% this afternoon, reaching $48.56 per share. In contrast, the average analyst target price for the stock is $63.23.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company is based in the United States. Bristol-Myers Squibb Company currently returns an annual dividend yield of 4.7%.
Make Sure to Consider the Following Before Buying Bristol-Myers Squibb Company:
-
Bristol-Myers Squibb Company has moved -38.0% over the last year.
-
BMY has a forward P/E ratio of 7.2 based on its EPS guidance of 6.7.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 3.8%.
-
The company has a price to earnings growth (PEG) ratio of -25.92.
-
Its Price to Book (P/B) ratio is 3.41
Bristol-Myers Squibb Company Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 11,850,000 | 1,130,000 | 10,720,000 | -10.28 |
| 2022 | 13,066,000 | 1,118,000 | 11,948,000 | -21.57 |
| 2021 | 16,207,000 | 973,000 | 15,234,000 | 14.55 |
| 2020 | 14,052,000 | 753,000 | 13,299,000 | 80.35 |
| 2019 | 8,210,000 | 836,000 | 7,374,000 | 20.59 |
| 2018 | 7,066,000 | 951,000 | 6,115,000 |
Bristol-Myers Squibb Company's free cash flows have a decent average of $10.78 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 283.9%. The compounded average growth rate over this period is 9.8%.
